|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0016360,
umls-concept:C0024202,
umls-concept:C0025677,
umls-concept:C0027651,
umls-concept:C0069515,
umls-concept:C0205460,
umls-concept:C0242957,
umls-concept:C0439828,
umls-concept:C0746319,
umls-concept:C0871261,
umls-concept:C1514559,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-3-6
|
|
pubmed:abstractText |
There is considerable interest in biologic markers able to predict the response of cancer patients to therapy. HER2 overexpression is a potential indicator of responsiveness to doxorubicin and paclitaxel and of unresponsiveness to tamoxifen in breast carcinoma patients. However, the significance of HER2 overexpression in responsiveness to cyclophosphamide, methotrexate, and fluorouracil (CMF) has remained unclear. In this study, we investigated this issue in the 386 breast cancer patients in the first CMF controlled clinical trial with a 20-year follow-up.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BiganzoliEE,
pubmed-author:BonadonnaGG,
pubmed-author:BoracchiPP,
pubmed-author:CasaliniPP,
pubmed-author:CascinelliNN,
pubmed-author:ColnaghiM IMI,
pubmed-author:GianniLL,
pubmed-author:MénardSS,
pubmed-author:MarubiniEE,
pubmed-author:PilottiSS,
pubmed-author:TomasicGG,
pubmed-author:ValagussaPP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
329-35
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11208823-Aged,
pubmed-meshheading:11208823-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11208823-Bayes Theorem,
pubmed-meshheading:11208823-Biological Markers,
pubmed-meshheading:11208823-Breast Neoplasms,
pubmed-meshheading:11208823-Chemotherapy, Adjuvant,
pubmed-meshheading:11208823-Cyclophosphamide,
pubmed-meshheading:11208823-Female,
pubmed-meshheading:11208823-Fluorouracil,
pubmed-meshheading:11208823-Humans,
pubmed-meshheading:11208823-Immunohistochemistry,
pubmed-meshheading:11208823-Lymphatic Metastasis,
pubmed-meshheading:11208823-Mastectomy, Radical,
pubmed-meshheading:11208823-Methotrexate,
pubmed-meshheading:11208823-Middle Aged,
pubmed-meshheading:11208823-Proportional Hazards Models,
pubmed-meshheading:11208823-Prospective Studies,
pubmed-meshheading:11208823-Receptor, erbB-2,
pubmed-meshheading:11208823-Survival Analysis
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
|
|
pubmed:affiliation |
Molecular Targeting Unit, Department of Experimental Oncology, Scientific Direction, Istituto Nazionale Tumori, Milan, Italy. menard@istitutotumori.mi.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
